GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

GH Research PLC

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oruka Therapeutics (ORKA), GH Research (GHRS) and Do...

Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA), GH Research (GHRS) and Doximity (DOCS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on GH Research (GHRS) and MapLight Therapeutics, Inc. (...

Analysts Are Bullish on Top Healthcare Stocks: GH Research (GHRS), MapLight Therapeutics, Inc. (MPLT)

An announcement from GH Research ( ($GHRS) ) is now available. On May 14, 2026, GH Research PLC entered into an at-the-market equity offering sales...

GH Research Launches $200 Million At-the-Market Share Offering With Stifel

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xtant Medical Holdings (XTNT) and GH Research (GHRS)...

Wall Street Analysts Are Bullish on Top Healthcare Picks

GH Research ( ($GHRS) ) has provided an announcement. On May 14, 2026, GH Research PLC filed a Form 6-K in the United States reporting its first-qu...

GH Research Posts Wider Q1 2026 Loss as R&D and Admin Costs Rise

GH Research ( ($GHRS) ) has issued an announcement. GH Research has called its 2026 annual general meeting for June 25, 2026, in Dublin, inviting s...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GHRS	$21.43	-7.83%	352.04K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GHRS	$21.43	-7.8%	352.04K
3
4
5
6

GHRS

GHRS

Recent News for GHRS

Get GH Research PLC Data in Excel

Get GH Research PLC Data in Excel